EL7.AI
StocksMedium•16 November 2026•
4 min read

Enanta Posts Quarterly Loss of $23.7 Million as Revenue Declines

Key Facts

1Net loss was $23.7 million, or $0.81 per diluted share, in the quarter ended September 30, 2026.
2Quarterly revenue fell to $12.9 million from $15.1 million a year earlier, and the company attributed the decline to lower AbbVie sales of MAVYRET/MAVIRET.
3Fiscal 2026 revenue was $63.0 million, and net loss was $68.2 million, or $2.35 per diluted share.
4The company said it had $194.5 million in cash, cash equivalents and securities as of September 30, 2026, and expects to fund operations and development programs through fiscal 2029.
5Enanta expects initial LOTUS data in the first quarter of 2027 and phase 2b RESOLVE data during 2027.

Enanta Pharmaceuticals reported on November 16, 2026, a net loss of $23.7 million, or $0.81 per diluted share, for the three months ended September 30, 2026. The loss in the year-earlier period was $18.7 million, or $0.87 per diluted share, meaning the loss widened in dollar terms while narrowing on a per-share basis. The company said in its results statement that quarterly revenue was $12.9 million. Available sources did not establish a consensus analyst estimate for the per-share loss, so it cannot be determined whether the result came in better than expected. The results show revenue declining as clinical trial spending increased, while the company relies on hepatitis C treatment royalties for part of its revenue.

Revenue for the quarter was $12.9 million, compared with $15.1 million in the same period of 2025. Enanta attributed the decline to lower global sales by AbbVie of the hepatitis C treatment known as MAVYRET/MAVIRET, which generated the royalty revenue recorded in the quarter. The company said all quarterly revenue came from these royalties. Investing.com estimated quarterly revenue at $12.86 million and said it came in below a consensus estimate of $15.7 million. This places the year-over-year revenue decline alongside the company’s stated reliance on sales of a single product marketed by AbbVie, as Enanta continues to develop its own research programs.

Research and development expenses rose to $26.1 million in the quarter ended September 30, 2026, from $23.8 million a year earlier. Enanta attributed the increase to higher clinical trial costs for its respiratory syncytial virus programs, driven by the RESOLVE and LOTUS studies. Quarterly research and development expenses exceeded the period’s reported revenue of $12.9 million, reflecting the scale of spending on treatment development relative to current royalty revenue. The company said enrollment was completed in the phase 2b LOTUS trial of zelicapavir in children with the virus. Enanta expects initial trial data in the first quarter of 2027. It also said dosing had begun in the phase 2b/3 RESOLVE trial in adults, with initial phase 2b data expected during 2027.

For the full fiscal year, Enanta reported revenue of $63.0 million for the year ended September 30, 2026, compared with $65.3 million in fiscal 2025. Annual net loss narrowed to $68.2 million, or $2.35 per diluted share, from $81.9 million, or $3.84 per share, in the prior year. The annual loss trend differed from the quarterly result: the full-year loss narrowed on both a net income and per-share basis, while net loss increased in the latest quarter from the year-earlier period. Revenue declined year over year both for the fiscal year and the quarter. The statement does not identify the reason for the annual improvement in net loss, so the company does not attribute it to any specific factor in these results.

Enanta reported that it had $194.5 million in cash, cash equivalents and marketable securities as of September 30, 2026. It said these resources, together with retained future royalties, are expected to fund current operations and development programs through fiscal 2029. The funding runway estimate comes as quarterly research and development expenses rose to $26.1 million, which the company attributed to RSV trial costs. The disclosure provides a stated time frame for funding existing programs, including the LOTUS and RESOLVE trials, without changing the reported reliance of quarterly revenue on royalties from an AbbVie product. The company had also announced that its CEO, Jay R. Luly, intends to retire by February 1, 2027, after 23 years leading the company.

Enanta shares closed at $10.67 on November 16, according to Investing.com. EL7 data showed the stock closing at $10.99 on November 13, a session before the results announcement, and does not represent the share price movement after publication. The evidence contained no verified data on the November 13 session’s trading range. Among the dates announced by the company are its participation in the Jefferies Global Healthcare Conference in London on November 18, 2026, followed by the ninth annual Evercore Healthcare Conference on December 2. Enanta said it plans to release its fiscal 2027 first-quarter results on February 8, 2027.

Open on chart